Monkeypox: WHO announces arrival of first vaccines in Democratic Republic of Congo in coming days

According to the World Health Organization, the first vaccines against mpox should arrive in the Democratic Republic of Congo in the coming days.

The World Health Organization announced this Friday, August 30, the arrival in the “next few days” of the first vaccines against mpox in the Democratic Republic of Congo, one of the African countries most affected by the epidemic.

“We hope that the first delivery will take place in the next few days”and more are expected to follow, the UN agency's director general, Dr Tedros Adhanom Ghebreyesus, told a news conference in Geneva after returning from the DRC.

According to WHO's Tim Nguyen, about 230,000 doses of the MVA-BN vaccine, produced by Danish pharmaceutical company Bavarian Nordic, would be “immediately available to be sent to affected areas”.

Few deaths in recent weeks

The resurgence of mpox in Africa, affecting the DRC and other countries on the continent, including Burundi, Kenya, Rwanda and Uganda, and the emergence of a new variant (1b) prompted the WHO to trigger its highest level of global health alert on 14 August.

Since the DRC is the country most affected by the new variant, “the largest portion” of the vaccines will be sent there, Dr Tedros said. Two subgroups of mpox are circulating in the DRC: clade 1a, in the west of the country, and clade 1b, in the east.

Dr Tedros said that more than 18,000 suspected cases of mpox had been reported in the DRC since the beginning of the year, with 629 deaths: “This includes more than 5,000 cases and 31 deaths in the eastern provinces of North and South Kivu, where the new clade 1b strain has propagated".

“The number of reported clade 1b cases has been increasing rapidly for several weeks. Fortunately, relatively few deaths have been reported in recent weeks,” the WHO chief observed. Outside the DRC, 258 cases of clade 1b have been confirmed in Burundi, 4 in Rwanda, 4 in Uganda, 2 in Kenya, 1 in Sweden and 1 in Thailand, according to the WHO.

“Six months”

“WHO is working to accelerate access to and distribution of vaccines,”Dr Tedros said, while stressing that vaccines were not the only tools to fight the disease.”“We believe we can end these epidemics in the next six months", he also assured.

The Strategic Advisory Group of Experts on Immunization (SAGE) recommends the use of MVA-BN and LC16 vaccines, which are produced by the Japanese company KM Biologics. However, they have not yet undergone full “prequalification” by WHO, a lengthy and complex process.

To address this situation, WHO has established an Emergency Use Listing, designed to expedite the availability of unlicensed medical products, such as vaccines needed in a public health emergency. Products on this list can thus be purchased and used by entities such as the UN children's agency UNICEF.

A targeted use of vaccines

Bavarian Nordic and KM Biologics finalized their application to WHO on August 23 and their review is ongoing, said WHO's Dr Mibongizi. But without waiting, “last week, I gave Gavi (the Vaccine Alliance, Editor's note) and UNICEF the green light to proceed with the procurement of vaccines, in parallel with the procedure for inclusion on the emergency list,” said Dr Tedros.

Furthermore, WHO is working with various partners to set up a coordination mechanism to allocate the donated doses. Dr Tedros also noted that the DRC itself approved both vaccines in June this year, and that the government has directly requested countries with large vaccine reserves to donate doses.

Finally, WHO is also working on plans to implement targeted use of the vaccines, as WHO does not advocate widespread vaccination, said Dr Maria Van Kerkhove, WHO's chief of epidemic and pandemic preparedness.

On 27 August, the WHO Africa office announced that Nigeria had received 10,000 doses of the vaccines, becoming the first African country to receive, outside of clinical trials, doses to respond to the epidemic. These vaccines, from Bavarian Nordic, were donated by the United States.

Add a Comment

Your email address will not be published. Required fields are marked *

(function(d,s){d.getElementById("licnt2061").src= "https://counter.yadro.ru/hit?t44.6;r"+escape(d.referrer)+ ((typeof(s)=="undefined")?"":";s"+s.width+"*"+s.height+"*"+ (s.colorDepth?s.colorDepth:s.pixelDepth))+";u"+escape(d.URL)+ ";h"+escape(d.title.substring(0,150))+";"+Math.random()}) (document,screen)